Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight loss in a real-world setting because patients discontinue treatment or ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

The analysis found that while the amount of weight regain varies by drug, there is a consistent pattern of rapid weight ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer and weight-loss therapy.

Adults with obesity were more likely to achieve a 10% or greater ... said weight loss observed in the study was lower than what has been reported in trials for both semaglutide and tirzepatide.

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...